OBJECTIVE: This pilot study evaluates efficacy of omega-3 fatty acid supplementation (Ω3), individual family psychoeducational psychotherapy (IF-PEP), and their combination in youth with subsyndromal bipolar disorders (bipolar disorder not otherwise specified [BP-NOS], cyclothymic disorder [CYC]). METHODS: This study was a 12 week, randomized trial of Ω3 versus placebo and IF-PEP versus active monitoring (AM) using a 2 × 2 design (Ω3 + PEP: n = 5; Ω3 + AM: n = 5; placebo + PEP: n = 7; placebo + AM: n = 6). Twenty-three youth ages 7-14 with BP-NOS or CYC were recruited via community advertisements and clinician referrals. Participants could be taking stable medication for attention-deficit/hyperactivity disorder and sleep aids, but no other psychotropics. Independent evaluators assessed participants at screen, baseline, and 2, 4, 6, 9, and 12 weeks. Primary outcome measures were the Kiddie Schedule for Affective Disorders (K-SADS) Depression (KDRS) and Mania (KMRS) Rating Scales, Children's Depression Rating Scale-Revised (CDRS-R), and Young Mania Rating Scale (YMRS). Ω3/placebo conditions were double-blind; independent evaluators were blind to psychotherapy condition. RESULTS: Most participants (83%) completed the 12 week trial. Side effects were uncommon and mild. Intent-to-treat analyses indicated significant improvement in depressive symptoms (KDRS) for combined treatment relative to placebo and AM (p = 0.01, d = 1.70). Across groups, manic symptoms improved over time without significant treatment effects. Effect of IF-PEP on child depression compared with AM was medium (d = 0.63, CDRS-R) to large (d = 1.24, KDRS). Effect of Ω3 on depression was medium (d = 0.48, KDRS). CONCLUSION:IF-PEP and Ω3 are well tolerated and associated with improved mood symptoms among youth with BP-NOS and CYC. Clinicaltrials.gov Identifier: NCT01507753.
RCT Entities:
OBJECTIVE: This pilot study evaluates efficacy of omega-3 fatty acid supplementation (Ω3), individual family psychoeducational psychotherapy (IF-PEP), and their combination in youth with subsyndromal bipolar disorders (bipolar disorder not otherwise specified [BP-NOS], cyclothymic disorder [CYC]). METHODS: This study was a 12 week, randomized trial of Ω3 versus placebo and IF-PEP versus active monitoring (AM) using a 2 × 2 design (Ω3 + PEP: n = 5; Ω3 + AM: n = 5; placebo + PEP: n = 7; placebo + AM: n = 6). Twenty-three youth ages 7-14 with BP-NOS or CYC were recruited via community advertisements and clinician referrals. Participants could be taking stable medication for attention-deficit/hyperactivity disorder and sleep aids, but no other psychotropics. Independent evaluators assessed participants at screen, baseline, and 2, 4, 6, 9, and 12 weeks. Primary outcome measures were the Kiddie Schedule for Affective Disorders (K-SADS) Depression (KDRS) and Mania (KMRS) Rating Scales, Children's Depression Rating Scale-Revised (CDRS-R), and Young Mania Rating Scale (YMRS). Ω3/placebo conditions were double-blind; independent evaluators were blind to psychotherapy condition. RESULTS: Most participants (83%) completed the 12 week trial. Side effects were uncommon and mild. Intent-to-treat analyses indicated significant improvement in depressive symptoms (KDRS) for combined treatment relative to placebo and AM (p = 0.01, d = 1.70). Across groups, manic symptoms improved over time without significant treatment effects. Effect of IF-PEP on childdepression compared with AM was medium (d = 0.63, CDRS-R) to large (d = 1.24, KDRS). Effect of Ω3 on depression was medium (d = 0.48, KDRS). CONCLUSION: IF-PEP and Ω3 are well tolerated and associated with improved mood symptoms among youth with BP-NOS and CYC. Clinicaltrials.gov Identifier: NCT01507753.
Authors: Amy E West; Sally M Weinstein; Amy T Peters; Andrea C Katz; David B Henry; Rick A Cruz; Mani N Pavuluri Journal: J Am Acad Child Adolesc Psychiatry Date: 2014-09-08 Impact factor: 8.829
Authors: Sarah M Conklin; Peter J Gianaros; Sarah M Brown; Jeffrey K Yao; Ahmad R Hariri; Stephen B Manuck; Matthew F Muldoon Journal: Neurosci Lett Date: 2007-06-02 Impact factor: 3.046
Authors: John S March; Susan Silva; Stephen Petrycki; John Curry; Karen Wells; John Fairbank; Barbara Burns; Marisa Domino; Steven McNulty; Benedetto Vitiello; Joanne Severe Journal: Arch Gen Psychiatry Date: 2007-10
Authors: L Eugene Arnold; Andrea S Young; Martha A Belury; Rachel M Cole; Barbara Gracious; Adina M Seidenfeld; Hannah Wolfson; Mary A Fristad Journal: J Child Adolesc Psychopharmacol Date: 2017-02-03 Impact factor: 2.576
Authors: Robert K McNamara; Jeffrey R Strawn; Max J Tallman; Jeffrey A Welge; L Rodrigo Patino; Thomas J Blom; Melissa P DelBello Journal: J Child Adolesc Psychopharmacol Date: 2020-03-11 Impact factor: 2.576
Authors: L Eugene Arnold; Mary A Fristad; Barbara L Gracious; Jeanette M Johnstone; Bonnie J Kaplan; Charles W Popper; Julia J Rucklidge Journal: Prim Care Companion CNS Disord Date: 2016-04-28
Authors: Andrea S Young; Molly R Meers; Anthony T Vesco; Adina M Seidenfeld; L Eugene Arnold; Mary A Fristad Journal: J Clin Child Adolesc Psychol Date: 2016-04-22
Authors: Mary A Fristad; Anthony T Vesco; Andrea S Young; K Zachary Healy; Elias S Nader; William Gardner; Adina M Seidenfeld; Hannah L Wolfson; L Eugene Arnold Journal: J Clin Child Adolesc Psychol Date: 2016-11-07
Authors: Vilma Gabbay; Rachel D Freed; Carmen M Alonso; Stefanie Senger; Jill Stadterman; Beth A Davison; Rachel G Klein Journal: J Clin Psychiatry Date: 2018-06-26 Impact factor: 4.384
Authors: Andrea S Young; Adina M Seidenfeld; K Zachary Healy; L Eugene Arnold; Mary A Fristad Journal: J Affect Disord Date: 2018-04-04 Impact factor: 4.839